WO2012087255A2 - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations Download PDF

Info

Publication number
WO2012087255A2
WO2012087255A2 PCT/TR2011/000274 TR2011000274W WO2012087255A2 WO 2012087255 A2 WO2012087255 A2 WO 2012087255A2 TR 2011000274 W TR2011000274 W TR 2011000274W WO 2012087255 A2 WO2012087255 A2 WO 2012087255A2
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical formulation
formulation according
formulations
pharmaceutically acceptable
imatinib
Prior art date
Application number
PCT/TR2011/000274
Other languages
French (fr)
Other versions
WO2012087255A3 (en
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2012087255A2 publication Critical patent/WO2012087255A2/en
Publication of WO2012087255A3 publication Critical patent/WO2012087255A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Definitions

  • the present invention relates to imatinib formulations comprising a pharmaceutically acceptable disintegrant in the range of 0.1% to 5% by weight and at least one other excipient.
  • Imatinib mesylate which is the methane sulfonic acid addition salt of imatinib, is available on the market under the trade name Glivec by Novartis AG.
  • Free base and pharmaceutically acceptable salts of imatinib are disclosed in the European patent numbered EP 0564409.
  • Imatinib which is a tyrosine kinase inhibitor is effective on BCR-ABL enzyme. Therefore, this compound is indicated for chronic myelogenous leukemia and acute lymphoblastic leukemia. In addition, it is known to inhibit trance membrane receptor KIT and PDGF receptors (Merck Index, 14 th Edition, no: 4902, page 851).
  • the active agent is marketed in 100 and 400 mg tablet and 100 mg capsule forms.
  • the prior art indicates various problems about the active agent and pharmaceutical formulations and dosage forms comprising it.
  • the patent numbered EP 1501485 describes dosage forms comprising high amounts of active agent in order to ensure therapeutic dose in leukemia treatment.
  • using high amounts of active agent in the formulations comprising imatinib also affects the physical characteristics of the dosage form obtained.
  • the patent numbered WO 03/090720 discloses that this problem is solved with dosage forms produced by wet granulation method.
  • wet granulation method is not a good choice for an active agent like imatinib which is highly prone to absorb moisture. In the dosage form produced by wet granulation method, it is not predictable for how long the active agent can remain stabile without absorbing moisture.
  • having content uniformity means to comprise equal amount of active agent in unit dosage form. Ensuring content uniformity is a pretty significant parameter for efficiency of the treatment.
  • dose of an active agent which is required to be contained in a capsule or a tablet in order to provide therapeutic effect is closely related to flow characteristics of the formulation comprising said active agent.
  • the inventor has found that sufficient flow characteristics and content uniformity can be ensured by using a disintegrant in the range of 0.1% to 5% by weight in the formulations comprising imatinib as active agent.
  • the present invention relates to pharmaceutical formulations comprising imatinib as active agent.
  • the pharmaceutical formulations of the present invention comprise at least 80%, preferably in the range of 80% to 99%, more preferably in the range of 80% to 98% of imatinib by weight.
  • imatinib refers to pharmaceutically acceptable salts, enantiomers, racemates, solvates, hydrates, different polymorphic forms, amorphous and crystalline forms or combinations thereof.
  • a characteristic feature of the pharmaceutical formulations of the present invention is that imatinib comprised in said formulations is mesylate salt of imatinib.
  • mesylate salt of imatinib comprised in said formulations is in alpha or beta crystalline form, more preferably in alpha crystalline form.
  • a characteristic feature of the pharmaceutical formulations of the present invention comprising imatinib as active agent is that said formulations comprise a pharmaceutically acceptable disintegrant in the range of 0.1% to 5% by weight and at least one other excipient in addition to the active agent.
  • a characteristic feature of the pharmaceutical formulations of the present invention comprising imatinib as active agent is that said formulations comprise a pharmaceutically acceptable disintegrant in the range of 0.1% to 3% by weight and at least one other excipient in addition to the active agent.
  • a characteristic feature of the pharmaceutical formulations of the present invention comprising imatinib as active agent is that said formulations comprise a pharmaceutically acceptable disintegrant in the range of 0.1% to 2% by weight and at least one other excipient in addition to the active agent.
  • a characteristic feature of the pharmaceutical formulations of the present invention comprising imatinib as active agent is that said formulations comprise a pharmaceutically acceptable disintegrant in the range of 0.1% to 1.75% by weight and at least one other excipient in addition to the active agent.
  • Excipients that can be used in the pharmaceutical formulations of the present invention can be selected from a group comprising binders, viscosity enhancing components, filling agents, drying agents, surfactants, stabilizing agents, lubricants, diluents, glidants, wetting agents, coating agents designed to provide various release characteristics, pH regulators, effervescent acids, effervescent bases, gelling agents, flavouring agents, sweeteners, emulsifying agents, anti-foam agents, protecting agents, solvents or solvent mixtures, coloring agents and complexing agents or combinations thereof.
  • a characteristic feature of the pharmaceutical formulations of the present invention comprising a pharmaceutically acceptable disintegrant in the range of 0.1% to 5% by weight in addition to imatinib as active agent is that said formulations comprise at least one other excipient selected from the group comprising lubricants, glidants, diluents, binders or combinations thereof.
  • a characteristic feature of the pharmaceutical formulations of the present invention comprising a pharmaceutically acceptable disintegrant in the range of 0.1% to 5% by weight and at least one other excipient in addition to imatinib as active agent is that the average particle size (d 50 ) of the disintegrant comprised in the formulations is finer than 100 ⁇ , preferably finer than 80 ⁇ , more preferably finer than 60 ⁇ , even more preferably in the range of 1 ⁇ to 60 ⁇ .
  • average particle size refers to volumetric average particle diameter and it is briefly displayed as d 50 .
  • d 50 refers that half of said substance by volume has a particle size above the value specified by d 50 and the other half has a particle size below the value specified by d 50.
  • d 50 particle size can be measured by one of the conventional measuring devices, for instance by a device which measures particle distribution by laser diffraction (for instance Malvern Mastersizer etc.).
  • the disintegrants that can be used in the formulations of the present invention can be selected from a group comprising carboxymethyl cellulose, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, microcrystalline cellulose, methyl cellulose, chitosan, starch, sodium starch glycolate or combinations thereof.
  • the disintegrant preferred in the formulations of the present invention is crospovidone.
  • the binders that can be used in the formulations of the present invention can be selected from a group comprising potato, wheat or corn starch; microcrystalline cellulose (Avicel®, Filtrak®, Heweten® or Pharmacel®), hydroxypropyl cellulose, hydroxyethyl cellulose; hydroxypropyl methyl cellulose (hydroxypropyl methyl cellulose- Type 2910 USP, hypromellose) and polyvinylpyrrolidone (for instance, Povidone® K30(BASF)), lactose, guar gum, pectin, gelatine, sodium alginate or combinations thereof.
  • microcrystalline cellulose Avicel®, Filtrak®, Heweten® or Pharmacel®
  • hydroxypropyl cellulose hydroxyethyl cellulose
  • hydroxypropyl methyl cellulose hydroxypropyl methyl cellulose- Type 2910 USP, hypromellose
  • polyvinylpyrrolidone for instance, Povidone® K30(BASF)
  • the lubricants that can be used in the formulations of the present invention can be selected from a group comprising metallic stearates (such as magnesium stearate, calcium stearate, aluminum stearate), fatty acid esters (such as sodium stearyl fumarate), fatty acids (such as stearic acid), fatty alcohols, glyceryl behenate, mineral oil, paraffins, hydrogenated vegetable oil, leucine, polyethylene glycols (PEG), metallic lauryl sulphates (such as sodium lauryl sulphate, magnesium lauryl sulphate), sodium chloride, sodium benzoate, sodium acetate, talc, siliconized talc and/or hydrates thereof or combinations thereof.
  • metallic stearates such as magnesium stearate, calcium stearate, aluminum stearate
  • fatty acid esters such as sodium stearyl fumarate
  • fatty acids such as stearic acid
  • fatty alcohols glyceryl behenate
  • the glidants that can be used in the formulations of the present invention can be selected from a group comprising silica, talc, colloidal silicone dioxide (Aerosil® 200, Syloid®, Cab-OSil®), magnesium trisilicate, cellulose powder, magnesium stearate and corn starch or combinations thereof.
  • the pharmaceutical formulations of the present invention which comprise a pharmaceutically acceptable disintegrant in the range of 0.1% to 5% by weight in addition to imatinib as active agent are in powder form.
  • the powder formulations of the present invention comprising a pharmaceutically acceptable disintegrant in the range of 0.1% to 5% by weight in addition to imatinib as active agent can be prepared in the form of any solid oral forms comprising tablet; layered tablet (for instance bilayer tablet); capsule; enterically coated or modified release tablets; controlled release tablet; prolonged release tablet; delayed release tablet; slow or fast release tablet; fast soluble tablet; effervescent tablet; fast soluble powder mixture; water soluble powder; pellet; mini tablet; micro tablet; granule capsule; pellet capsule; mini tablet capsule; micro tablet capsule or dry powder mixture for syrup preparation; dragee; orodispersible tablet; film tablet or combinations thereof.
  • the powder formulations of the present invention comprising a pharmaceutically acceptable disintegrant in the range of 0.1% to 5% by weight in addition to imatinib as active agent
  • the capsule of the present invention can be made of a substance selected from the group comprising gelatine, chitosan, starch and/or starch derivatives, cellulose and/or cellulose derivatives or synthetic polymers.
  • the capsule is made of telescoping cap and body parts.
  • cap and body parts can be made of the same or different materials.
  • the capsule material can be selected from a group comprising hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, hydroxy methyl cellulose, hydroxy ethyl cellulose or combinations thereof in the case that the capsule is made of cellulose or derivatives thereof.
  • the capsule material can be selected from a group comprising polyethylene polyester, polyethylene terephthalate, polycarbonate or polypropylene or combinations thereof in the case that the capsule is made of synthetic polymer.
  • polyethylene glycol of various molecular weights sorbitol, glycerol, propylene glycol, titanium dioxide, polyethylene oxide-polypropylene oxide block copolymers and/or other polyalcohols and polyethers
  • the capsule material is gelatine.
  • the capsule preferred is gelatine capsule and said capsule can be in any shape and color.
  • powder formulations of the present invention are prepared in tablet dosage form
  • said tablet dosage form can be coated with protective coating, enteric coating, film coating and/or coatings designed to provide various release characteristics (fast release, slow release, controlled release).
  • the film coating materials that can be used in scope of the invention can be selected from a group comprising cellulose derivatives such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose hydroxyl ethyl cellulose, methyl hydroxyl ethyl cellulose and sodium carboxymethyl cellulose; iron oxides; titanium oxide; polyvinyl alcohols such as polyethylene glycol; synthetic polymers such as polyvinyl acetal diethyl aminoacetate, aminoalkyl methacrylate copolymers and polyvinylpyrrolidone; and polysaccharides such as pullulan or combinations thereof.
  • cellulose derivatives such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose hydroxyl ethyl cellulose, methyl hydroxyl ethyl cellulose and sodium carboxymethyl cellulose
  • iron oxides titanium oxide
  • polyvinyl alcohols such as polyethylene glycol
  • synthetic polymers such as polyvinyl acetal diethyl aminoacetate, aminoal
  • the enteric coating materials that can be used in scope of the present invention can be selected from a group comprising cellulose derivatives such as hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethyl cellulose, cellulose acetate phthalate; acrylic acid derivatives such as methacrylic acid copolymer L, methacrylic acid copolymer LD and methacrylic acid copolymer S; and natural substances such as shellac or combinations thereof.
  • Effective dose amount required to be taken daily can vary according to factors such as patient's age, personal conditions, phase of the disease, mode of administration. For instance, daily imatinib dose amount required for adults varies in the range of 400 mg to 800 mg.
  • the amount of active agent in oral dosage form is in the range of 50 mg to 800 mg, preferably in the range of 100 mg to 600 mg, more preferably in the range of 100 mg to 400 mg in the case that the active agent is imatinib free base in another embodiment of the present invention.
  • the active agent is a pharmaceutically acceptable derivative of imatinib
  • these substances are used in an equivalent amount to imatinib in the range of 50 mg to 800 mg, preferably in the range of 100 mg to 600 mg, more preferably in the range of 100 mg to 400 mg.
  • the amount of imatinib comprised in the pharmaceutical formulations corresponds to imatinib free base in the range of 50 mg to 800 mg, preferably in the range of 100 mg to 600 mg, more preferably in the range of 100 mg to 400 mg.
  • the oral dosage form comprising an effective amount of alpha crystalline form of imatinib mesylate can be administered separately, sequentially and simultaneously with oral dosage forms comprising active agents belonging to groups such as rapamycin, cyclosporine, ascomycin, corticosteroid, cyclophosphamide, azathioprine, methotrexate, brequinar, leflunomide, mizoribine, mycophenolic acid and/or mycophenolate mofetil.
  • active agents belonging to groups such as rapamycin, cyclosporine, ascomycin, corticosteroid, cyclophosphamide, azathioprine, methotrexate, brequinar, leflunomide, mizoribine, mycophenolic acid and/or mycophenolate mofetil.
  • the pharmaceutical capsule formulations of the present invention comprising a pharmaceutically acceptable disintegrant in the range of 0.1% to 5% by weight and at least one other excipient in addition to imatinib as active agent are preferably produced by dry blending method.
  • the pharmaceutical capsule formulations of the present invention comprising a pharmaceutically acceptable disintegrant in the range of 0.1% to 5% by weight and at least one other excipient in addition to imatinib as active agent are used in the treatment of diseases of acute lymphocytic leukemia, gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome, chronic myelogenous leukemia (CML), myelodysplastic syndrome and systemic mastocytosis.
  • GIST gastrointestinal stromal tumors
  • CML chronic myelogenous leukemia
  • myelodysplastic syndrome myelodysplastic syndrome and systemic mastocytosis.
  • imatinib mesylate and the other excipients are mixed homogenously.
  • the mixture is preferably presented as filled into hard gelatine capsules which are made of titanium dioxide and gelatine.
  • imatinib mesylate and the other excipients are mixed homogenously.
  • the mixture is compressed in tablet form and coated with film coating.

Abstract

The present invention relates to imatinib formulations comprising a pharmaceutically acceptable disintegrant in the range of 0.1% to 5% by weight and at least one other excipient.

Description

PHARMACEUTICAL FORMULATIONS
The present invention relates to imatinib formulations comprising a pharmaceutically acceptable disintegrant in the range of 0.1% to 5% by weight and at least one other excipient. Imatinib mesylate, which is the methane sulfonic acid addition salt of imatinib, is available on the market under the trade name Glivec by Novartis AG. Free base and pharmaceutically acceptable salts of imatinib (Formula 1) are disclosed in the European patent numbered EP 0564409.
Figure imgf000002_0001
(Formula I) Imatinib which is a tyrosine kinase inhibitor is effective on BCR-ABL enzyme. Therefore, this compound is indicated for chronic myelogenous leukemia and acute lymphoblastic leukemia. In addition, it is known to inhibit trance membrane receptor KIT and PDGF receptors (Merck Index, 14th Edition, no: 4902, page 851).
It is also known that the compound displays polymorphic structure. The patent application numbered WO9903854 discloses that the compound is a β crystalline form of methanesulfonate salt. The product produced according to the patent numbered EP0564409 is a crystalline form. In the patent application numbered EP1857454, on the other hand, crystalline form I form of the compound is described.
Imatinib free base and its salts were first described in the patent numbered EP 564409. The patent application numbered WO2004074502, on the other hand, refers to acid addition salts of imatinib and production methods thereof.
The active agent is marketed in 100 and 400 mg tablet and 100 mg capsule forms.
The prior art indicates various problems about the active agent and pharmaceutical formulations and dosage forms comprising it. For instance, the patent numbered EP 1501485 describes dosage forms comprising high amounts of active agent in order to ensure therapeutic dose in leukemia treatment. On the other hand, using high amounts of active agent in the formulations comprising imatinib also affects the physical characteristics of the dosage form obtained. The patent numbered WO 03/090720 discloses that this problem is solved with dosage forms produced by wet granulation method.
However, wet granulation method is not a good choice for an active agent like imatinib which is highly prone to absorb moisture. In the dosage form produced by wet granulation method, it is not predictable for how long the active agent can remain stabile without absorbing moisture.
Consequently, when the prior art is taken into consideration, it is seen that new approaches are needed for pharmaceutical formulations comprising high amounts of imatinib in order to ensure appropriate bioavailability.
As a result of studies conducted in parallel with this need, the inventor has brought a solution to the problems existing in the prior art with pharmaceutical powder formulations prepared by mixing the active agent with appropriate amounts of excipients having appropriate characteristics.
However, another unexpected problem was encountered in course of production of these new formulations prepared in scope of the present invention. The inventor observed that the powder formulation comprising active agent and appropriate excipients agglomerates along the production line; and sufficient flow and content uniformity cannot be ensured in the formulations.
For pharmaceutical formulations, having content uniformity means to comprise equal amount of active agent in unit dosage form. Ensuring content uniformity is a pretty significant parameter for efficiency of the treatment. In other terms, dose of an active agent which is required to be contained in a capsule or a tablet in order to provide therapeutic effect is closely related to flow characteristics of the formulation comprising said active agent. The inventor has found that sufficient flow characteristics and content uniformity can be ensured by using a disintegrant in the range of 0.1% to 5% by weight in the formulations comprising imatinib as active agent. Detailed Description of the Invention
The present invention relates to pharmaceutical formulations comprising imatinib as active agent.
The pharmaceutical formulations of the present invention comprise at least 80%, preferably in the range of 80% to 99%, more preferably in the range of 80% to 98% of imatinib by weight.
The term "imatinib" used here refers to pharmaceutically acceptable salts, enantiomers, racemates, solvates, hydrates, different polymorphic forms, amorphous and crystalline forms or combinations thereof.
A characteristic feature of the pharmaceutical formulations of the present invention is that imatinib comprised in said formulations is mesylate salt of imatinib.
Another characteristic of the pharmaceutical formulations of the present invention is that mesylate salt of imatinib comprised in said formulations is in alpha or beta crystalline form, more preferably in alpha crystalline form.
A characteristic feature of the pharmaceutical formulations of the present invention comprising imatinib as active agent is that said formulations comprise a pharmaceutically acceptable disintegrant in the range of 0.1% to 5% by weight and at least one other excipient in addition to the active agent.
A characteristic feature of the pharmaceutical formulations of the present invention comprising imatinib as active agent is that said formulations comprise a pharmaceutically acceptable disintegrant in the range of 0.1% to 3% by weight and at least one other excipient in addition to the active agent.
A characteristic feature of the pharmaceutical formulations of the present invention comprising imatinib as active agent is that said formulations comprise a pharmaceutically acceptable disintegrant in the range of 0.1% to 2% by weight and at least one other excipient in addition to the active agent. A characteristic feature of the pharmaceutical formulations of the present invention comprising imatinib as active agent is that said formulations comprise a pharmaceutically acceptable disintegrant in the range of 0.1% to 1.75% by weight and at least one other excipient in addition to the active agent. Excipients that can be used in the pharmaceutical formulations of the present invention can be selected from a group comprising binders, viscosity enhancing components, filling agents, drying agents, surfactants, stabilizing agents, lubricants, diluents, glidants, wetting agents, coating agents designed to provide various release characteristics, pH regulators, effervescent acids, effervescent bases, gelling agents, flavouring agents, sweeteners, emulsifying agents, anti-foam agents, protecting agents, solvents or solvent mixtures, coloring agents and complexing agents or combinations thereof.
A characteristic feature of the pharmaceutical formulations of the present invention comprising a pharmaceutically acceptable disintegrant in the range of 0.1% to 5% by weight in addition to imatinib as active agent is that said formulations comprise at least one other excipient selected from the group comprising lubricants, glidants, diluents, binders or combinations thereof.
The inventor, on the other hand, has also found that particle size of the disintegrant comprised in the formulations is a significant parameter for ensuring effective mixing and flow characteristics in the formulations. Accordingly, a characteristic feature of the pharmaceutical formulations of the present invention comprising a pharmaceutically acceptable disintegrant in the range of 0.1% to 5% by weight and at least one other excipient in addition to imatinib as active agent is that the average particle size (d50) of the disintegrant comprised in the formulations is finer than 100 μπι, preferably finer than 80 μπι, more preferably finer than 60 μιη, even more preferably in the range of 1 μπι to 60 μηι.
The term "average particle size" used here refers to volumetric average particle diameter and it is briefly displayed as d50. In this regard, the term d50 refers that half of said substance by volume has a particle size above the value specified by d50 and the other half has a particle size below the value specified by d50. According to the invention, d50 particle size can be measured by one of the conventional measuring devices, for instance by a device which measures particle distribution by laser diffraction (for instance Malvern Mastersizer etc.).
According to this, the disintegrants that can be used in the formulations of the present invention can be selected from a group comprising carboxymethyl cellulose, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, microcrystalline cellulose, methyl cellulose, chitosan, starch, sodium starch glycolate or combinations thereof. The disintegrant preferred in the formulations of the present invention is crospovidone.
According to this, the binders that can be used in the formulations of the present invention can be selected from a group comprising potato, wheat or corn starch; microcrystalline cellulose (Avicel®, Filtrak®, Heweten® or Pharmacel®), hydroxypropyl cellulose, hydroxyethyl cellulose; hydroxypropyl methyl cellulose (hydroxypropyl methyl cellulose- Type 2910 USP, hypromellose) and polyvinylpyrrolidone (for instance, Povidone® K30(BASF)), lactose, guar gum, pectin, gelatine, sodium alginate or combinations thereof. According to this, the lubricants that can be used in the formulations of the present invention can be selected from a group comprising metallic stearates (such as magnesium stearate, calcium stearate, aluminum stearate), fatty acid esters (such as sodium stearyl fumarate), fatty acids (such as stearic acid), fatty alcohols, glyceryl behenate, mineral oil, paraffins, hydrogenated vegetable oil, leucine, polyethylene glycols (PEG), metallic lauryl sulphates (such as sodium lauryl sulphate, magnesium lauryl sulphate), sodium chloride, sodium benzoate, sodium acetate, talc, siliconized talc and/or hydrates thereof or combinations thereof.
According to this, the glidants that can be used in the formulations of the present invention can be selected from a group comprising silica, talc, colloidal silicone dioxide (Aerosil® 200, Syloid®, Cab-OSil®), magnesium trisilicate, cellulose powder, magnesium stearate and corn starch or combinations thereof.
The pharmaceutical formulations of the present invention which comprise a pharmaceutically acceptable disintegrant in the range of 0.1% to 5% by weight in addition to imatinib as active agent are in powder form. The powder formulations of the present invention comprising a pharmaceutically acceptable disintegrant in the range of 0.1% to 5% by weight in addition to imatinib as active agent can be prepared in the form of any solid oral forms comprising tablet; layered tablet (for instance bilayer tablet); capsule; enterically coated or modified release tablets; controlled release tablet; prolonged release tablet; delayed release tablet; slow or fast release tablet; fast soluble tablet; effervescent tablet; fast soluble powder mixture; water soluble powder; pellet; mini tablet; micro tablet; granule capsule; pellet capsule; mini tablet capsule; micro tablet capsule or dry powder mixture for syrup preparation; dragee; orodispersible tablet; film tablet or combinations thereof. The powder formulations of the present invention comprising a pharmaceutically acceptable disintegrant in the range of 0.1% to 5% by weight in addition to imatinib as active agent are preferably in tablet or capsule dosage form.
In the case that the powder formulations of the present invention are in capsule form, the capsule of the present invention can be made of a substance selected from the group comprising gelatine, chitosan, starch and/or starch derivatives, cellulose and/or cellulose derivatives or synthetic polymers. In addition to this, the capsule is made of telescoping cap and body parts. In said capsule, cap and body parts can be made of the same or different materials.
According to the present invention, the capsule material can be selected from a group comprising hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, hydroxy methyl cellulose, hydroxy ethyl cellulose or combinations thereof in the case that the capsule is made of cellulose or derivatives thereof.
According to the present invention, the capsule material can be selected from a group comprising polyethylene polyester, polyethylene terephthalate, polycarbonate or polypropylene or combinations thereof in the case that the capsule is made of synthetic polymer.
According to the present invention; polyethylene glycol of various molecular weights, sorbitol, glycerol, propylene glycol, titanium dioxide, polyethylene oxide-polypropylene oxide block copolymers and/or other polyalcohols and polyethers can be used as additive in the case that the capsule material is gelatine. In the case that powder formulations of the present invention are prepared in capsule dosage form, the capsule preferred is gelatine capsule and said capsule can be in any shape and color.
In the case that powder formulations of the present invention are prepared in tablet dosage form, said tablet dosage form can be coated with protective coating, enteric coating, film coating and/or coatings designed to provide various release characteristics (fast release, slow release, controlled release).
The film coating materials that can be used in scope of the invention can be selected from a group comprising cellulose derivatives such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose hydroxyl ethyl cellulose, methyl hydroxyl ethyl cellulose and sodium carboxymethyl cellulose; iron oxides; titanium oxide; polyvinyl alcohols such as polyethylene glycol; synthetic polymers such as polyvinyl acetal diethyl aminoacetate, aminoalkyl methacrylate copolymers and polyvinylpyrrolidone; and polysaccharides such as pullulan or combinations thereof. The sugar-based coating materials that can be used in scope of the present invention can be selected from a group comprising saccharose alone or optionally any one of talc, calcium carbonate, calcium phosphate, calcium sulphate, gelatine, gum Arabic, polyvinylpyrrolidone and pullulan or any combination thereof.
The enteric coating materials that can be used in scope of the present invention can be selected from a group comprising cellulose derivatives such as hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethyl cellulose, cellulose acetate phthalate; acrylic acid derivatives such as methacrylic acid copolymer L, methacrylic acid copolymer LD and methacrylic acid copolymer S; and natural substances such as shellac or combinations thereof. Effective dose amount required to be taken daily can vary according to factors such as patient's age, personal conditions, phase of the disease, mode of administration. For instance, daily imatinib dose amount required for adults varies in the range of 400 mg to 800 mg. According to this, the amount of active agent in oral dosage form is in the range of 50 mg to 800 mg, preferably in the range of 100 mg to 600 mg, more preferably in the range of 100 mg to 400 mg in the case that the active agent is imatinib free base in another embodiment of the present invention. In the case that the active agent is a pharmaceutically acceptable derivative of imatinib, on the other hand, these substances are used in an equivalent amount to imatinib in the range of 50 mg to 800 mg, preferably in the range of 100 mg to 600 mg, more preferably in the range of 100 mg to 400 mg. According to this, the amount of imatinib comprised in the pharmaceutical formulations corresponds to imatinib free base in the range of 50 mg to 800 mg, preferably in the range of 100 mg to 600 mg, more preferably in the range of 100 mg to 400 mg.
According to another embodiment of the present invention, the oral dosage form comprising an effective amount of alpha crystalline form of imatinib mesylate can be administered separately, sequentially and simultaneously with oral dosage forms comprising active agents belonging to groups such as rapamycin, cyclosporine, ascomycin, corticosteroid, cyclophosphamide, azathioprine, methotrexate, brequinar, leflunomide, mizoribine, mycophenolic acid and/or mycophenolate mofetil.
The pharmaceutical capsule formulations of the present invention comprising a pharmaceutically acceptable disintegrant in the range of 0.1% to 5% by weight and at least one other excipient in addition to imatinib as active agent are preferably produced by dry blending method.
The pharmaceutical capsule formulations of the present invention comprising a pharmaceutically acceptable disintegrant in the range of 0.1% to 5% by weight and at least one other excipient in addition to imatinib as active agent are used in the treatment of diseases of acute lymphocytic leukemia, gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome, chronic myelogenous leukemia (CML), myelodysplastic syndrome and systemic mastocytosis.
The examples below are given in order to render the invention more comprehensible. To this respect, scope of the invention is not limited to these examples in any ways. EXAMPLE 1: Imatinib Capsule Formulation
Figure imgf000010_0001
For production of the formulation given, imatinib mesylate and the other excipients are mixed homogenously.
The mixture is preferably presented as filled into hard gelatine capsules which are made of titanium dioxide and gelatine.
EXAMPLE 2: Imatinib Tablet Formulation
Figure imgf000010_0002
For production of the formulation given, imatinib mesylate and the other excipients are mixed homogenously.
The mixture is compressed in tablet form and coated with film coating.

Claims

A pharmaceutical formulation comprising imatinib characterized in that said formulation comprises a pharmaceutically acceptable disintegrant in the range of 0.1% to 5% by weight and at least one other excipient.
The pharmaceutical formulation according to claim 1 characterized in that said formulation comprises a pharmaceutically acceptable disintegrant in the range of 0.1% to 3% by weight and at least one other excipient.
The pharmaceutical formulation according to claims 1-2 characterized in that said formulation comprises a pharmaceutically acceptable disintegrant in the range of 0.1% to 2% by weight and at least one other excipient.
The pharmaceutical formulation according to claims 1-3 characterized in that said formulation comprises a pharmaceutically acceptable disintegrant in the range of 0.1% to 1.75% by weight and at least one other excipient.
The pharmaceutical formulation according to any preceding claims characterized in that said formulation comprises at least one other excipient selected from a group comprising binders, viscosity enhancing components, filling agents, drying agents, surfactants, stabilizing agents, lubricants, diluents, glidants, wetting agents, coating agents designed to provide various release characteristics, pH regulators, effervescent acids, effervescent bases, gelling agents, flavouring agents, sweeteners, emulgators, anti-foam agents, protecting agents, solvent or solvent mixtures, coloring agents and complexing agents or combinations thereof.
The pharmaceutical formulation according to claim 5 characterized in that said formulation comprises at least one other excipient selected from a group comprising lubricants, glidants, diluents, binders or combinations thereof.
The capsule formulation according to any preceding claims characterized in that the average particle size of the pharmaceutically acceptable disintegrant comprised in said formulations is finer than 100 μηι.
The pharmaceutical formulation according to claims 1-7 characterized in that the average particle size of the pharmaceutically acceptable disintegrant comprised in said formulations is finer than 80 μπι.
The pharmaceutical formulation according to claims 1-8 characterized in that the average particle size of the pharmaceutically acceptable disintegrant comprised in said formulations is finer than 60 μπι.
10. The pharmaceutical formulation according to claims 1-9 characterized in that the average particle size of the pharmaceutically acceptable disintegrant comprised in said formulations is in the range of 1 μπι to 60 μπι.
11. The pharmaceutical formulation according to any preceding claims characterized in that the pharmaceutically acceptable disintegrant is selected from a group comprising carboxymethyl cellulose, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, microcrystalline cellulose, methyl cellulose, chitosan, starch, sodium starch glycolate or combinations thereof.
12. The pharmaceutical formulation according to any preceding claims characterized in that imatinib comprised in said formulations is in the form of pharmaceutically acceptable salts, enantiomers, racemates, solvates, hydrates, different polymorphic forms, amorphous and crystalline forms of imatinib or combinations thereof.
13. The pharmaceutical formulation according to claim 12 characterized in that imatinib comprised in said formulations is imatinib mesylate salt.
14. The pharmaceutical formulation according to claims 12-13 characterized in that imatinib comprised in said formulations is alpha crystalline form of imatinib mesylate salt.
15. The pharmaceutical formulation according to any preceding claims characterized in that said formulations are in tablet form.
16. The pharmaceutical formulation according to any preceding claims characterized in that said formulations are in capsule form.
17. The pharmaceutical formulation according to any preceding claims characterized in that the disintegrant is crospovidone.
PCT/TR2011/000274 2010-12-20 2011-12-19 Pharmaceutical formulations WO2012087255A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/10618A TR201010618A2 (en) 2010-12-20 2010-12-20 An oral dosage form comprising imatinib and the manufacture of an oral dosage form
TR2010/10618 2010-12-20

Publications (2)

Publication Number Publication Date
WO2012087255A2 true WO2012087255A2 (en) 2012-06-28
WO2012087255A3 WO2012087255A3 (en) 2012-08-16

Family

ID=45529174

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/TR2011/000276 WO2012087257A2 (en) 2010-12-20 2011-12-19 Oral dosage form comprising imatinib and production of said oral dosage form
PCT/TR2011/000275 WO2012087256A2 (en) 2010-12-20 2011-12-19 Pharmaceutical capsule formulations
PCT/TR2011/000274 WO2012087255A2 (en) 2010-12-20 2011-12-19 Pharmaceutical formulations

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/TR2011/000276 WO2012087257A2 (en) 2010-12-20 2011-12-19 Oral dosage form comprising imatinib and production of said oral dosage form
PCT/TR2011/000275 WO2012087256A2 (en) 2010-12-20 2011-12-19 Pharmaceutical capsule formulations

Country Status (2)

Country Link
TR (1) TR201010618A2 (en)
WO (3) WO2012087257A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2497464A3 (en) * 2011-03-09 2012-09-19 Adamed SP. Z O.O. Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture
WO2014081172A1 (en) * 2012-11-22 2014-05-30 에스케이케미칼 (주) Effervescent super-disintegrating imatinib preparation and production method for same
WO2014139836A1 (en) * 2013-03-15 2014-09-18 Pharmaceutical Oriented Services Ltd Pharmaceutical compositions comprising imatinib
EP2803352A1 (en) * 2013-05-14 2014-11-19 Hetero Research Foundation High dose imatinib tablets
US20160143850A1 (en) * 2013-07-09 2016-05-26 Shilpa Medicare Limited Oral Pharmaceutical Compositions Comprising Imatinib Mesylate
WO2019229648A1 (en) * 2018-05-28 2019-12-05 Shivalik Rasayan Limited Oral compositions of imatinib mesylate

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI608849B (en) * 2014-06-16 2017-12-21 國邑藥品科技股份有限公司 High drug load pharmaceutical compositions with controllable release rate and production methods thereof
EP3257499A1 (en) 2016-06-17 2017-12-20 Vipharm S.A. Process for preparation of imatinib methanesulfonate capsules

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564409A1 (en) 1992-04-03 1993-10-06 Ciba-Geigy Ag Pyrimidin derivatives and process for their preparation
WO1999003854A1 (en) 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
WO2003090720A1 (en) 2002-04-23 2003-11-06 Novartis Ag High drug load tablet
WO2004074502A2 (en) 2003-02-18 2004-09-02 Cipla Ltd A process of preparing imatinib
EP1857454A1 (en) 2006-05-15 2007-11-21 Chemagis Ltd. Crystalline imatinib base and production process therefor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI992711A1 (en) * 1999-12-27 2001-06-27 Novartis Ag ORGANIC COMPOUNDS
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
DE602006012671D1 (en) * 2005-06-03 2010-04-15 Elan Pharma Int Ltd NANOTEHOUS IMATINIB MESYLATE FORMULATIONS
ATE445392T1 (en) * 2005-08-15 2009-10-15 Siegfried Generics Int Ag FILM TABLET OR GRANULES CONTAINING A PYRIDYLPYRIMIDINE
MX2009002336A (en) * 2006-09-01 2009-03-20 Teva Pharma Imatinib compositions.
WO2009042809A1 (en) * 2007-09-25 2009-04-02 Teva Pharmaceutical Industries Ltd. Stable imatinib compositions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564409A1 (en) 1992-04-03 1993-10-06 Ciba-Geigy Ag Pyrimidin derivatives and process for their preparation
WO1999003854A1 (en) 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
WO2003090720A1 (en) 2002-04-23 2003-11-06 Novartis Ag High drug load tablet
EP1501485A1 (en) 2002-04-23 2005-02-02 Novartis AG High drug load tablet
WO2004074502A2 (en) 2003-02-18 2004-09-02 Cipla Ltd A process of preparing imatinib
EP1857454A1 (en) 2006-05-15 2007-11-21 Chemagis Ltd. Crystalline imatinib base and production process therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Merck Index", pages: 851

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2497464A3 (en) * 2011-03-09 2012-09-19 Adamed SP. Z O.O. Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture
WO2014081172A1 (en) * 2012-11-22 2014-05-30 에스케이케미칼 (주) Effervescent super-disintegrating imatinib preparation and production method for same
WO2014139836A1 (en) * 2013-03-15 2014-09-18 Pharmaceutical Oriented Services Ltd Pharmaceutical compositions comprising imatinib
EP2803352A1 (en) * 2013-05-14 2014-11-19 Hetero Research Foundation High dose imatinib tablets
US20160143850A1 (en) * 2013-07-09 2016-05-26 Shilpa Medicare Limited Oral Pharmaceutical Compositions Comprising Imatinib Mesylate
EP3019159A4 (en) * 2013-07-09 2017-01-18 Shilpa Medicare Limited Oral pharmaceutical compositions comprising imatinib mesylate
WO2019229648A1 (en) * 2018-05-28 2019-12-05 Shivalik Rasayan Limited Oral compositions of imatinib mesylate

Also Published As

Publication number Publication date
WO2012087255A3 (en) 2012-08-16
WO2012087257A3 (en) 2012-09-27
WO2012087256A3 (en) 2012-09-27
WO2012087257A2 (en) 2012-06-28
TR201010618A2 (en) 2012-07-23
WO2012087256A2 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
WO2012087255A2 (en) Pharmaceutical formulations
US9180101B2 (en) Pharmaceutical composition simultaneously having rapid-acting property and long-acting property
ES2820536T3 (en) Novel pharmaceutical composition
DK2790699T3 (en) PHARMACEUTICAL COMPOSITION WITH IMPROVED BIOTAILITY FOR HYDROPHOBIC CONNECTION WITH HIGH MELDING POINT
ES2935800T3 (en) Ketamine Oral Dosage Form
EP2854759B1 (en) Dosage forms comprising apixaban and matrix former
KR20160101720A (en) Pharmaceutical compositions comprising azd9291
ES2644698T3 (en) Modified Release Formulation
CA2858522A1 (en) Methods for treating cardiovascular disorder
EP2961383A1 (en) Suspension for oral administration comprising amorphous tolvaptan
CN107405311B (en) Apremilast sustained release preparation
WO2019130749A1 (en) Novel fine particle coating (drug-containing hollow particle and method for manufacturing same)
ES2414384T3 (en) Modified release composition comprising ranolazine
BR112013003158B1 (en) pharmaceutical compositions of metabotropic glutamate receptor antagonists 5 (mglu5)
WO2018095996A1 (en) Delayed release dosage forms comprising dimethyl fumarate
AU2017244982A1 (en) Film-coated tablet having high chemical stability of active ingredient
JP2023036924A (en) Pharmaceutical composition containing lenalidomide
WO2013008253A2 (en) Imatinib formulations
WO2019131891A1 (en) Bitterness-masked drug-containing particles and formulation containing said drug-containing particles
JP6626492B2 (en) Capsule dosage form of metoprolol succinate
CN108096251B (en) Gefitinib pharmaceutical composition and preparation method thereof
ES2898456T3 (en) Pharmaceutical composition comprising a triazole antifungal agent and method of preparing the same
JP2013536832A (en) Milnacipran controlled release pharmaceutical composition
WO2017174096A1 (en) Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
ES2818249T3 (en) Pharmaceutical composition comprising an atypical antipsychotic agent and method for its preparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11811588

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11811588

Country of ref document: EP

Kind code of ref document: A2